Immunotherapy for Multiple Myeloma:Advances and Challenges
10.13865/j.cnki.cjbmb.2025.04.1510
- VernacularTitle:多发性骨髓瘤的免疫治疗:成果与挑战
- Author:
Meng WANG
1
;
Chun-Yan SUN
1
Author Information
1. 华中科技大学同济医学院协和医院血液科,武汉 430022
- Publication Type:Journal Article
- Keywords:
multiple myeloma(MM);
immunotherapy;
monoclonal antibodies(mAbs);
chimeric anti-gen receptor T-cells(CAR-T);
antibody-drug conjugates(ADCs);
bispecific antibodies(BsAbs)
- From:
Chinese Journal of Biochemistry and Molecular Biology
2025;41(6):774-782
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma(MM)is a hematologic malignancy characterized by the malignant prolifer-ation of plasma cells.Currently,proteasome inhibitors(PIs),immunomodulatory drugs(IMiDs),and autologous hematopoietic stem cell transplantation(ASCT)are the primary approaches used to improve the survival outcomes of MM patients.However,as treatment advances,most patients still face refractory and relapsed diseases,and the path to a cure remains challenging.In recent years,monoclonal antibod-ies(mAbs),chimeric antigen receptor T cells(CAR-T),antibody-drug conjugates(ADCs),and bispe-cific antibodies(BsAbs)have all demonstrated promising efficacy in clinical studies and applications.These antibody and cell-based immunotherapies have brought new hope to patients with refractory and re-lapsed MM(RRMM).Each type of immunotherapy offers unique advantages in activating immune cells,targeting tumors,and improving patient outcomes,yet they also encounter challenges related to safety and resistance.In the future,with continuous advancements in molecular biology and antibody engineering,novel immunotherapeutic products are expected to achieve synergistic effects through combination strate-gies,thereby providing longer survival benefits and improved life quality for RRMM patients.This article aims to review the latest progress in immunotherapy for MM,systematically discussing the mechanisms of action,current clinical applications,and future development trends of mAbs,CAR-T,ADCs,and BsAbs.It is intended to serve as a comprehensive reference for researchers and clinicians and promote advancing precision immunotherapy for MM.
